The global injectable drug delivery market growth forecasted to transform from USD 754.5 billion in 2024 to USD 1139.4 billion by 2029, driven by a CAGR of 8.6%. Growth of this market is mainly driven by increasing prevalence of Infectious diseases, Increasing technological advancements and increasing funding scenarios for R&D for the Injectable drug delivery market.

Injectable Drug Delivery Market Trends

Download an Illustrative overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150

Browse in-depth TOC on "Injectable Drug Delivery Market"

350 - Tables

50 - Figures

450 – Pages

"By Therapeutic application, Infectious diseases holds the largest share in 2023."

Injectable vaccinations prevent infectious diseases by activating the immune system to create antibodies against certain organisms. Vaccines are delivered intramuscularly or subcutaneously to produce immunity to diseases such as influenza, measles, polio, hepatitis, and COVID-19, among others. Injectable drugs are widely used to treat chronic infectious disorders like tuberculosis (TB) and HIV/AIDS. To efficiently target the TB germs and prevent medication resistance, TB treatment frequently combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin. Similarly, injectable antiretroviral medications can be used in HIV/AIDS therapy regimens to reduce viral replication and prevent disease progression.

"By Usage Pattern Curative Care holds the largest share in 2023."

Based on usage patterns, the Injectable drug delivery market is segmented into curative care, Immunization, and Other usage patterns. Curative care holds the largest share during the forecast period. Injectable drugs are frequently utilised in curative care settings, such as hospitals and emergency rooms, to treat acute medical illnesses that require prompt attention. For example, injectable antibiotics, antivirals, and analgesics may be used to treat infections, pain, and other acute symptoms, allowing for faster recovery and resolution of the illness. Injectable medication delivery allows for precise administration of targeted medicines based on unique patient characteristics, genetic profiles, and illness biomarkers. Targeted therapies, such as monoclonal antibodies, immunotherapies, and gene therapies, are injected to specifically target cancer cells, alter immune responses, or correct genetic abnormalities, resulting in cures or disease-modifying effects.

"Hospitals are the fastest-growing end users of the Injectable drug delivery market in 2023."

Based on end users, the Injectable drug delivery market is segmented into Hospitals and Retail Pharmacy centres. Hospitals serve a wide range of medical disciplines, including surgery, cancer, cardiology, neurology, infectious diseases, and others, all of which may necessitate injectable drugs for diagnosis, treatment, or prevention. Injectable medications are utilised in a variety of medical fields to provide targeted therapies, perform diagnostic tests, and offer supportive care to patients. Hospitals perform a variety of medical procedures and interventions, including surgeries, diagnostic imaging, interventional radiology, and therapeutic interventions, which may necessitate the use of injectable drugs before, during, or following the treatment. Injectable medications are used extensively in anesthesia, sedation, pain management, contrast enhancement, and other procedures, which contributes to the overall demand for injectable drug delivery in hospital settings.

"North America dominates the global Injectable drug delivery market in 2023."

The Injectable drug delivery market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023 North America accounted for the largest share during the forecast period due to the following reasons- North America has one of the world's highest healthcare costs, thanks to innovative medical technologies, expensive prescription drug prices, and a comprehensive healthcare insurance system. The readiness to invest in novel healthcare solutions, such as injectable drug delivery systems, helps to drive market growth and adoption in the region. North America is home to world-class clinical research institutes, university medical centres, and pharmaceutical research hubs that perform clinical trials, translational research, and technology development for injectable drug delivery. Collaborations among academia, industry, and government organizations promote innovation and the translation of scientific discoveries into clinical practice.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=150

Injectable Drug Delivery Market Dynamics:

Drivers:

• Increased Prevalence of Chronic Diseases

Restraints:

• Infections associated with needlestick injuries

Opportunities:

• Increase in demand for biosimilars and generic medicine

Challenge:

• Preference for other modes of drug delivery

Key Market Players of Injectable Drug Delivery Industry:

The prominent companies are Becton, Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Baxter International, Inc. (U.S.), Sandoz (Germany), Terumo (Japan), Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), Bespak (U.K.), and B. Braun Melsungen (Germany).

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=150

Recent Developments of Injectable Drug Delivery Industry:

• In Sep 2022 BD launched BD EffivaxTM Glass prefillable syringes. This syringe will help in growing demand for vaccines manufacturing.
• In Oct 2022 GSK received its product approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) for immunization during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants younger than two months old.)
• In Nov 2023 Eli and Lilly received FDA approval for Zepbound injection which is the first and only obesity medication.

Injectable Drug Delivery Market - Key Benefits of Buying the Report:

This report studies the Injectable drug delivery market based on type, formulation packaging, site of administration, route of administration, facility of use, distribution channels and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (increasing chronic diseases, increasing biologics, technological advancements) ,restraints (Infections associated with needle stick injuries), challenges(Other methods of Injectable drug delivery available in the market), opportunities (Increase in the demand of generic medicines and biosimilars) contributing the growth of the Injectable drug delivery market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Injectable drug delivery market.
• Market Development: Comprehensive information on the lucrative emerging markets by type, formulation packaging, by site of administration,facility of use and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the Injectable drug delivery market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Injectable drug delivery market.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/